



Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg

Worli, Mumbai – 400 030, India

Tel. : + 91 22 6663 5456

Fax : + 91 22 6663 5460

Email : auro@aurolabs.com

Web : www.aurolabs.com

Reg. Off / Mfg. Unit :

K-56, M.I.D.C. Tarapur,

Dist. Palghar, Maharashtra – 401506

CIN No. L33125MH1989PLC051910

July 31, 2023

The Listing Department

BSE Limited

Phiroz Jeejeebhoy Towers

Dalal Street, Fort, Mumbai - 400 001

Scrip ID/Code : 530233
Subject : Outcome of Board Meeting dated July 31, 2023
Ref : Regulation 30 & Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. July 31, 2023) has inter-alia:

1. Considered and approved the Unaudited Financial Results of the Company for the quarter ended on June 30, 2023 as recommended by the Audit Committee:

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the quarter ended on June 30, 2023
- Limited Review Report received from the Statutory Auditors of the Company


The results are also being uploaded on website of the Company at www.aurolabs.com.

2. Considered and approved change in Statutory Auditors of the Company:

M/s Khurdia Jain & Co., Chartered Accountants, FRN: 120263W, have tendered their resignation from the position of Statutory Auditors of the Company with effect from the close of business hours on July 31, 2023 and the Board has, subject to the approval of members in ensuing AGM, approved appointment of M/s Kothari Jain & Associates, Chartered Accountants, (FRN 113041W) as the Statutory Auditors of the Company to fill up the casual vacancy.

Further, the Board has also recommended appointment of M/s Kothari Jain & Associates, Chartered Accountants, (FRN 113041W) as statutory auditors for a period of five years to hold office from the conclusion of the 34th AGM till the conclusion of 39th AGM to be held in the year 2027.

A separate disclosure in this regard, is submitted with the stock exchanges informing the changes in Statutory Auditors.



3. Policy on determination of materiality for disclosure of events or information

Considered and approved Revised 'Policy for Determination of Materiality for Disclosure of events or information' in line with SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2023.

4. Considered and approved the Cost Statement for the financial year 2022-23

The Board, on recommendation of the Audit Committee considered and approved the Cost Statements with annexures for the manufactured product of the Company for the financial year ended on March 31, 2023 and took note of the report of Cost Auditors thereon.

5. Considered and approved re-appointment of Cost Auditors of the Company

Based on the recommendation of the Audit Committee, the Board of Directors of the Company considered and approved re-appointment of M/s Poddar & Co., Cost Accountants, (Firm Registration No: 101734), Mumbai as the Cost Auditors of the Company for conducting the audit of cost records for the financial year 2023-2024.

The meeting of the Board of Directors commenced at 02.00 PM and concluded at 04.00 PM.

This intimation is also being uploaded on Company's website at www.aurolabs.com.

The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

Kindly take the above on your record.

Thanking you,

Yours Faithfully,

For, Auro Laboratories Limited

Siddhartha Deorah

(Siddhartha Deorah)

Whole Time Director

DIN: 00230796



Encl: A/a

AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

(Rs. In Lakhs except EPS)					
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023					
Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2023 (Unaudited)	31.03.2023 (Ref. Note 4)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1	Revenue from Operations	1,018.26	1,352.49	1,118.52	5,289.42
2	Other Income	36.45	61.93	5.10	94.13
3	Total Income (1 + 2)	1,054.71	1,414.42	1,123.62	5,383.55
4	Expenses				
	a. Cost of raw material consumed	719.62	634.03	792.53	3,730.48
	b. Purchase of Stock-in-trade	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	(122.92)	120.64	(70.86)	-161.01
	d. Employee benefits expense	83.80	142.57	115.34	472.38
	e. Finance Cost	26.74	13.41	26.16	81.42
	f. Depreciation and amortisation expenses	27.00	30.42	25.00	107.42
	g. Other Expenses	222.44	220.14	223.99	808.30
	Total Expenses (4)	956.68	1,161.21	1,112.16	5,038.99
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	98.03	253.21	11.46	344.56
6	Exceptional items				
7	Profit / (Loss) before tax (5 ± 6)	98.03	253.21	11.46	344.56
8	Tax expense				
	(a) Current tax expenses for current year	27.27	74.67	3.19	100.08
	(b) MAT credit (where applicable)				
	(c) Deferred tax	-	0.28	-	0.28
9	Profit / (Loss) for the period from continuing operation (7± 8)	70.76	178.26	8.27	244.20
10	Profit / (Loss) for discontinuing operations	-	-	-	-
11	Tax expense of discontinuing operations				
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)	-	-	-	-
13	Profit / (Loss) for the period (after tax) (9 ± 12)	70.76	178.26	8.27	244.20
14	Other Comprehensive Income				
	A. Items that will not be reclassified subsequently to profit or loss				
	(i) Items that will not be reclassified to profit or loss	18.05	48.85	(0.07)	48.85
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(5.02)	(13.59)	-	(13.59)
	B. Items that will be reclassified subsequently to profit or loss	-	-	-	-
	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income /(loss), net of tax (14)	13.03	35.26	(0.07)	35.26
15	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)] (13 ± 14)	83.79	213.52	8.20	279.46
16	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25
17	Other Equity				2,796.80
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):				
	(a) Basic	1.14	2.86	0.13	3.92
	(b) Diluted	1.14	2.86	0.13	3.92



Notes on financial results:-

- 1) The above unaudited financial results for the quarter ended June 30, 2023 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on July 31, 2023
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) Limited Review has been carried out by the Statutory Auditors of the Company.
- 4) Figures of the Quarter ended on March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the published year to the date upto the third quarter of the respective financial year.
- 5) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

Siddhartha Deorah
(SIDDHARTHA DEORAH)

WHOLE TIME DIRECTOR

DIN: 00230796



Place : Mumbai

Date : 31/07/2023



KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS

To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter ended June 30, 2023, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants



Sampat Khurdia
Partner
Membership No. 033615
Firm Reg. No. 120263W
Place: Mumbai
Date: 31st July 2023
UDIN: 23033615BGZGPP2666

